The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

AbbVie Inc. closed 17.25% short of its 52-week high of $207.32, which the company achieved on October 31st.

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.